UB Paderborn / Katalog / Suche / in CDI

Efficacy of RG7787, a next-generation mesothelin-targeted immunotoxin, against triple-negative breast and gastric cancers

Molecular cancer therapeutics, 2014-11, Vol.13 (11), p.2653-2661

2014

Link zum Volltext

Verfügbarkeit prüfen

Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes

Proceedings of the National Academy of Sciences - PNAS, 2012-07, Vol.109 (29), p.11782-11787

2012

Link zum Volltext

Verfügbarkeit prüfen

A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity

Blood, 2009-04, Vol.113 (16), p.3792-3800

2009

Link zum Volltext

Verfügbarkeit prüfen

Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes

Proceedings of the National Academy of Sciences - PNAS, 2011-04, Vol.108 (14), p.5742-5747

2011

Link zum Volltext

Verfügbarkeit prüfen

immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes

Proceedings of the National Academy of Sciences - PNAS, 2008-08, Vol.105 (32), p.11311-11316

2008

Link zum Volltext

Verfügbarkeit prüfen

A recombinant immunotoxin against the tumor-associated antigen mesothelin reengineered for high activity, low off-target toxicity, and reduced antigenicity

Molecular cancer therapeutics, 2013-01, Vol.12 (1), p.48-57

2013

Link zum Volltext

Verfügbarkeit prüfen

Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors

Proceedings of the National Academy of Sciences - PNAS, 2007-10, Vol.104 (43), p.17099-17104

2007

Link zum Volltext

Verfügbarkeit prüfen

Killing of Resistant Cancer Cells with Low Bak by a Combination of an Antimesothelin Immunotoxin and a TRAIL Receptor 2 Agonist Antibody

Clinical cancer research, 2011-09, Vol.17 (18), p.5926-5934

2011

Link zum Volltext

Verfügbarkeit prüfen

Immunotoxin resistance via reversible methylation of the DPH4 promoter is a unique survival strategy

Proceedings of the National Academy of Sciences - PNAS, 2012-05, Vol.109 (18), p.6898-6903

2012

Link zum Volltext

Verfügbarkeit prüfen

A Flow Cytometry Method to Quantitate Internalized Immunotoxins Shows that Taxol Synergistically Increases Cellular Immunotoxins Uptake

Cancer research (Chicago, Ill.), 2010-02, Vol.70 (3), p.1082-1089

2010

Link zum Volltext

Verfügbarkeit prüfen

Mesothelin Expression in Advanced Gastroesophageal Cancer Represents a Novel Target for Immunotherapy

Applied immunohistochemistry & molecular morphology, 2016-04, Vol.24 (4), p.246

2016

Link zum Volltext

Verfügbarkeit prüfen

Synergistic Antitumor Activity of Taxol and Immunotoxin SS1P in Tumor-Bearing Mice

Clinical cancer research, 2006-08, Vol.12 (15), p.4695-4701

2006

Link zum Volltext

Verfügbarkeit prüfen

Enhanced transfection efficiency of a systemically delivered tumor-targeting immunolipoplex by inclusion of a pH-sensitive histidylated oligolysine peptide

Nucleic acids research, 2004-03, Vol.32 (5), p.e48

2004

Link zum Volltext

Verfügbarkeit prüfen

Actinomycin D enhances killing of cancer cells by immunotoxin RG7787 through activation of the extrinsic pathway of apoptosis

Proceedings of the National Academy of Sciences - PNAS, 2016-09, Vol.113 (38), p.10666-10671

2016

Link zum Volltext

Verfügbarkeit prüfen

Immunoglobulin Superfamily Receptor Translocation Associated 2 Protein on Lymphoma Cell Lines and Hairy Cell Leukemia Cells Detected by Novel Monoclonal Antibodies

Clinical cancer research, 2005-01, Vol.11 (1), p.87-96

2005

Link zum Volltext

Verfügbarkeit prüfen

Recombinant Immunotoxin with T-cell Epitope Mutations That Greatly Reduce Immunogenicity for Treatment of Mesothelin-Expressing Tumors

Molecular cancer therapeutics, 2015-12, Vol.14 (12), p.2789-2796

2015

Link zum Volltext

Verfügbarkeit prüfen

Ankrd26 Gene Disruption Enhances Adipogenesis of Mouse Embryonic Fibroblasts

The Journal of biological chemistry, 2011-08, Vol.286 (31), p.27761-27768

2011

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1290: Actinomycin D enhanced immunotoxin RG7787 killing of cancer cells

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.1290-1290

2016

Link zum Volltext

Verfügbarkeit prüfen

Antitumor effects of immunotoxins are enhanced by lowering HCK or treatment with SRC kinase inhibitors

Molecular cancer therapeutics, 2014-01, Vol.13 (1), p.82-89

2014

Link zum Volltext

Verfügbarkeit prüfen

A Modified Form of Diphthamide Causes Immunotoxin Resistance in a Lymphoma Cell Line with a Deletion of the WDR85 Gene

The Journal of biological chemistry, 2013-04, Vol.288 (17), p.12305-12312

2013

Link zum Volltext

Verfügbarkeit prüfen

Inhibitory effects of the combination of HER-2 antisense oligonucleotide and chemotherapeutic agents used for the treatment of human breast cancer

Cancer gene therapy, 2001-10, Vol.8 (10), p.728-739

2001

Link zum Volltext

Verfügbarkeit prüfen

Decreased Expression of Diphthamide Genes Is Responsible for the Resistance to the Anti-CD22 Immunotoxin Moxetumomab Pasudotox (m. pasudotox) in Acute Lymphoblastic Leukemia (ALL)/Non-Hodgkin Lymphoma (NHL) Cell Lines

Blood, 2012-11, Vol.120 (21), p.2443-2443

2012

Link zum Volltext

Verfügbarkeit prüfen

Killing of Resistant Cancer Cells with Low Bak by a Combination of an Anti-mesothelin Immunotoxin and a TRAIL Receptor 2 Agonist Antibody

Clinical cancer research, 2011-08, Vol.17 (18), p.5926-5934

2011

Link zum Volltext

Verfügbarkeit prüfen

CAPC negatively regulates NF-κB activation and suppresses tumor growth and metastasis

Oncogene, 2012-03, Vol.31 (13), p.1673-1682

2012

Link zum Volltext

Verfügbarkeit prüfen

Methylation of the DPH1 promoter causes immunotoxin resistance in acute lymphoblastic leukemia cell line KOPN-8

Leukemia research, 2013-11, Vol.37 (11), p.1551-1556

2013

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Efficacy of RG7787, a next-generation mesothelin-targeted immunotoxin, against triple-negative breast and gastric cancers

Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes

A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity

Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes

immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes

A recombinant immunotoxin against the tumor-associated antigen mesothelin reengineered for high activity, low off-target toxicity, and reduced antigenicity

Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors

Killing of Resistant Cancer Cells with Low Bak by a Combination of an Antimesothelin Immunotoxin and a TRAIL Receptor 2 Agonist Antibody

Immunotoxin resistance via reversible methylation of the DPH4 promoter is a unique survival strategy

A Flow Cytometry Method to Quantitate Internalized Immunotoxins Shows that Taxol Synergistically Increases Cellular Immunotoxins Uptake

Mesothelin Expression in Advanced Gastroesophageal Cancer Represents a Novel Target for Immunotherapy

Synergistic Antitumor Activity of Taxol and Immunotoxin SS1P in Tumor-Bearing Mice

Enhanced transfection efficiency of a systemically delivered tumor-targeting immunolipoplex by inclusion of a pH-sensitive histidylated oligolysine peptide

Actinomycin D enhances killing of cancer cells by immunotoxin RG7787 through activation of the extrinsic pathway of apoptosis

Immunoglobulin Superfamily Receptor Translocation Associated 2 Protein on Lymphoma Cell Lines and Hairy Cell Leukemia Cells Detected by Novel Monoclonal Antibodies

Recombinant Immunotoxin with T-cell Epitope Mutations That Greatly Reduce Immunogenicity for Treatment of Mesothelin-Expressing Tumors

Ankrd26 Gene Disruption Enhances Adipogenesis of Mouse Embryonic Fibroblasts

Abstract 1290: Actinomycin D enhanced immunotoxin RG7787 killing of cancer cells

Antitumor effects of immunotoxins are enhanced by lowering HCK or treatment with SRC kinase inhibitors

A Modified Form of Diphthamide Causes Immunotoxin Resistance in a Lymphoma Cell Line with a Deletion of the WDR85 Gene

Inhibitory effects of the combination of HER-2 antisense oligonucleotide and chemotherapeutic agents used for the treatment of human breast cancer

Decreased Expression of Diphthamide Genes Is Responsible for the Resistance to the Anti-CD22 Immunotoxin Moxetumomab Pasudotox (m. pasudotox) in Acute Lymphoblastic Leukemia (ALL)/Non-Hodgkin Lymphoma (NHL) Cell Lines

Killing of Resistant Cancer Cells with Low Bak by a Combination of an Anti-mesothelin Immunotoxin and a TRAIL Receptor 2 Agonist Antibody

CAPC negatively regulates NF-κB activation and suppresses tumor growth and metastasis

Methylation of the DPH1 promoter causes immunotoxin resistance in acute lymphoblastic leukemia cell line KOPN-8

Suchergebnisse filtern